Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Skin Cancer
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
Immunosuppression Tied to Poor Outcomes in Multiple Cutaneous SCC
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
Chemotherapy-Stimulated Immune Response: An Open Debate
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.
FDA Calls for Patient Registries to Track Robotically Treated Cancers
Head-to-head comparisons of these types of surgical interventions are still needed, according to the regulatory body.
Drug Shortages Threaten Childhood Cancer Treatment
Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.
BiTE Antibody Constructs and Treatment-Resistant Metastatic Melanoma
Researchers suggest using novel therapies that act by a distinct mechanism of action to boost durable response rates in patients with treatment-resistant metastatic melanoma.
Next post in AACR 2019
